Drug Price Wars: A Fierce Struggle for Affordability
Okay, here’s a breakdown of the provided text, summarizing the key details:
Main Topic: Drug Pricing and Access in Switzerland (and europe)
Key points:
* Image: The article features an image of modeling pastels, seemingly unrelated to the content.
* Article title: “Who decides on the price of drugs and how?”
* Publication date: April 23, 2024
* summary: The article explains the complex process of determining the price of medicines.
* Pricing Based on Value: Pharmaceutical groups generally agree with pricing drugs based on their value (effectiveness, benefits to patients).
* Disagreements & Delays: There are frequent disagreements between pharmaceutical companies and health authorities on how to apply value-based pricing. This leads to lengthy negotiations.
* Reduced Access: These delays in negotiations are impacting patient access to new drugs. A study (W.A.I.T.) shows that access to newly approved treatments in Europe has decreased from 42% in 2019 to 29% in 2024.
* Link: The article links to a study by the European Federation of Pharmaceutical Associations and Industries (EFPIA) for more information.
In essence, the article highlights a growing problem: while the principle of value-based drug pricing is accepted, disagreements over implementation are slowing down access to potentially life-saving medications for patients.